PMID- 30555158
OWN - NLM
STAT- In-Data-Review
LR  - 20190123
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 120
IP  - 2
DP  - 2019 Jan
TI  - (Pro)renin receptor promotes colorectal cancer through the Wnt/beta-catenin
      signalling pathway despite constitutive pathway component mutations.
PG  - 229-237
LID - 10.1038/s41416-018-0350-0 [doi]
AB  - BACKGROUND: Although constitutive activating mutations in the Wnt/beta-catenin
      signalling pathway are important for colorectal cancer development, canonical
      signalling through Wnt ligands is essential for beta-catenin activation. Here, we
      investigated the role of (pro)renin receptor ((P)RR), a component of the Wnt
      receptor complex, in the pathogenesis of colorectal cancer. METHODS: (P)RR
      silencing was performed in human colorectal cancer cells containing constitutive 
      activating mutations in the Wnt/beta-catenin pathway. (P)RR overexpression was
      induced in normal colon epithelial cells. Protein and mRNA levels of pathway
      components were detected, and Wnt signalling activity was measured using a
      beta-catenin reporter. Cell proliferative activity and apoptosis were evaluated
      using WST-1 assay and flow cytometry. Xenografts were induced in nude mice.
      RESULTS: (P)RR expression was greater in colorectal cancer tissues and cells than
      in normal colorectal samples. Patients with strong (P)RR expression took more
      proportion in groups with poorly-differentiated, advanced and rapidly-progressing
      cancers. (P)RR silencing attenuated the pathway in colorectal cancer cells,
      impaired their proliferation in vitro and vivo. (P)RR overexpression enhanced the
      pathway and proliferation of normal colon epithelial cells. CONCLUSIONS: Aberrant
      (P)RR expression promotes colorectal cancer through the Wnt/beta-catenin
      signalling pathway despite constitutive pathway-activating mutations. (P)RR is a 
      potential diagnostic and therapeutic target for colorectal cancer.
FAU - Wang, Juan
AU  - Wang J
AD  - Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang
      University School of Medicine, Hangzhou, 310009, Zhejiang Province, China.
AD  - Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa,
      761-0793, Japan.
AD  - Department of Immuno-oncology, Fourth Affiliated Hospital of Hebei Medical
      University, Shijiazhuang, 050000, Hebei Province, China.
FAU - Shibayama, Yuki
AU  - Shibayama Y
AD  - Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa,
      761-0793, Japan.
FAU - Zhang, Anqi
AU  - Zhang A
AD  - Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa,
      761-0793, Japan.
FAU - Ohsaki, Hiroyuki
AU  - Ohsaki H
AD  - Department of Medical Biophysics, Kobe University Graduate School of Health
      Sciences, Kobe, 650-0017, Japan.
FAU - Asano, Eisuke
AU  - Asano E
FAU - Suzuki, Yasuyuki
AU  - Suzuki Y
AD  - Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa
      University, Kagawa, 761-0793, Japan.
FAU - Kushida, Yoshio
AU  - Kushida Y
AD  - Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University,
      Kagawa, 761-0793, Japan.
FAU - Kobara, Hideki
AU  - Kobara H
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa
      University, Kagawa, 761-0793, Japan.
FAU - Masaki, Tsutomu
AU  - Masaki T
AD  - Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa
      University, Kagawa, 761-0793, Japan.
FAU - Wang, Zhiyu
AU  - Wang Z
AD  - Department of Immuno-oncology, Fourth Affiliated Hospital of Hebei Medical
      University, Shijiazhuang, 050000, Hebei Province, China.
FAU - Nishiyama, Akira
AU  - Nishiyama A
AD  - Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa,
      761-0793, Japan. akira@med.kagawa-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20181217
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
EDAT- 2018/12/18 06:00
MHDA- 2018/12/18 06:00
CRDT- 2018/12/18 06:00
PHST- 2018/08/27 00:00 [received]
PHST- 2018/11/14 00:00 [accepted]
PHST- 2018/10/31 00:00 [revised]
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2018/12/18 06:00 [medline]
PHST- 2018/12/18 06:00 [entrez]
AID - 10.1038/s41416-018-0350-0 [doi]
AID - 10.1038/s41416-018-0350-0 [pii]
PST - ppublish
SO  - Br J Cancer. 2019 Jan;120(2):229-237. doi: 10.1038/s41416-018-0350-0. Epub 2018
      Dec 17.